We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Bio-Techne

Bio-Techne Corporation is a developer and manufacturer of high-quality purified proteins and reagent solutions - nota... read more Featured Products: More products

Download Mobile App




Bio-Techne and ALZpath Partner to Advance Neurodegenerative Disease Research and Treatment

By LabMedica International staff writers
Posted on 19 Nov 2024
Print article
Image: The Simple Plex Human Phospho Tau 217 ALZpath assay runs on the Ella automated immunoassay platform (Photo courtesy of Bio-Techne)
Image: The Simple Plex Human Phospho Tau 217 ALZpath assay runs on the Ella automated immunoassay platform (Photo courtesy of Bio-Techne)

Bio-Techne Corporation (Minneapolis, MN, USA) and ALZpath, Inc. (Carlsbad, CA, USA) have entered into a strategic partnership to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The collaboration leverages Bio-Techne's Ella fully automated, multiplexing immunoassay platform and ALZpath's proprietary pTau217 antibody to provide the Simple Plex Human Phospho-Tau (T217) ALZpath Assay.

The ALZpath pTau217 (phosphorylated Tau217) antibody is the leading antibody used to detect the pTau217 biomarker. Increased levels of pTau217 are associated with amyloid plaques and tau tangles, the hallmark features of Alzheimer's disease. By running the Simple Plex Human Phospho Tau 217 ALZpath Assay on the Ella system, researchers will be able to detect the pTau217 signal in less invasive sample collection types, such as plasma samples, in just 90 minutes without any manual intervention, improving efficiency, scalability, and precision while providing the required information to help accelerate clinical decisions.

"Our partnership with ALZpath represents a major step forward in our commitment to advancing neurodegenerative disease research," said Will Geist, President of Bio-Techne's Protein Sciences Segment. "We're excited to see the impact that this easy-to-use, hands-free platform will have on advancing research in this critical field."

"As cases of Alzheimer's disease continue to rise around the world, this collaboration provides an opportunity to leverage our proprietary pTau217 antibody to advance promising research and development of new treatments," said Chad Holland, CEO at ALZpath. "The integration of our pTau217 antibody into Bio-Techne's advanced immunoassay technology creates a unique toolset that will empower researchers around the world to explore new methods of treatment and validate benefits that may result from those interventions, pushing the industry forward."

Related Links:
Bio-Techne Corporation

ALZpath, Inc.

New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Gold Member
Rotavirus Rapid Test
Rotavirus Cassette
New
Thyroxine ELISA
T4 ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: Representative examples of FW images (Photo courtesy of Alzheimer’s & Dementia, doi.org/10.1002/alz.14408)

Cost-Effective Blood Test Could Detect Early Brain Changes Leading to Dementia

Dysfunctional cells in the blood vessels of the brain have increasingly been identified as a major factor in the development of cerebral small vessel disease (CSVD), which is a significant cause of cognitive... Read more

Hematology

view channel
Image: Personalized blood count could lead to early intervention for common diseases (Photo courtesy of 123RF)

Personalized CBC Testing Could Help Diagnose Early-Stage Diseases in Healthy Individuals

A complete blood count (CBC) screening is a standard examination most physicians request for healthy adults. This test is essential for evaluating a patient’s overall health with a single blood sample.... Read more

Immunology

view channel
Image: Concept for the device. Memory B cells able to bind influenza virus remain stuck to channels despite shear forces (Photo courtesy of Steven George/UC Davis)

Microfluidic Chip-Based Device to Measure Viral Immunity

Each winter, a new variant of influenza emerges, posing a challenge for immunity. People who have previously been infected or vaccinated against the flu may have some level of protection, but how well... Read more

Microbiology

view channel
Image: The BIOFIRE® FILMARRAY® Tropical Fever Panel has received U.S. FDA Special 510(k) clearance (Photo courtesy of bioMérieux)

Syndromic PCR Test Rapidly and Accurately Identifies Pathogens in Patients with Tropical Fever Infections

Tropical fevers refer to infections that are common in, or unique to, tropical and subtropical regions. As these diseases spread to previously unaffected areas and can be brought in by travelers, infections... Read more

Pathology

view channel
Image: These images show the high resolution achieved with the new microscopy technique (Photo courtesy of Cao, R. et al. Science Advance, 2024. Caltech)

New Microscopy Technique Enables Rapid Tumor Analysis by Surgeons in OR

The current standard method for quickly sampling and imaging tissue during surgery involves taking a biopsy, freezing the sample, staining it to enhance visibility, and slicing it into thin sections that... Read more

Technology

view channel
Image: Site-selective immobilization of different bioreceptors on individual field-effect transistors, achieved through the use of thermal scanning probe lithography (Photo courtesy of NYU Tandon)

FET-Based Sensors Pave Way for Portable Diagnostic Devices Capable of Detecting Multiple Diseases

In a world facing a wide range of health challenges, from rapidly spreading viruses to chronic diseases and drug-resistant bacteria, the demand for fast, reliable, and user-friendly home diagnostic tests... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.